Good chance. Kwality Pharmaceuticals Ltd. Historical trend: Incorporated 1983, ANVISA and EU GMP certified manufacturer of pharma products incl. complex molecules, generics, cephalosporin, beta-lactam, oncology, biologics - portfolio of 3000+ formulations across 25+ therapeutic areas. Excellent accelerating growth: Sales grew from 69Cr (Mar2023) to 157Cr (Mar2026), NP from -7Cr to 25Cr, OPM expanding steadily 17% to 25%. Dec2025 NP 16Cr/123Cr sales, Mar2026 NP 25Cr/157Cr sales - strong finish. 5yr profit CAGR 34.5%, 10yr median sales growth 24%. Strong returns: ROCE 24.1%, ROE 22.7% (3yr ROE 18.1%), PEG reasonable at 1.38. Positive: expected good quarter ahead flagged by Screener. Cons: rich valuation at PE 39.9x and 8.13x book value, no dividend despite profits, high debtor days 204. Strong pharma growth story with expanding margins; good chance but valuation full.

#MacroViews#Miscellaneous#EquityResearch#FundamentalViews#PersonalFinance

722 likes·73 comments